Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients

BACKGROUND: Little is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+. METHODS: We used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between 2000 and 2009. We estimated the adjusted percent of patients who received antineoplastic agents, by type, number, and their costs 12 months following diagnosis. We report the percent of patients who received 3 or more of commonly prescribed agents and estimate survival for the 24-month period following diagnosis by age and treatment. RESULTS: The percentage that received 3 or more agents increased from 3% to 73% in colon patients aged 65-74 and from 2% to 53% in patients 75+. Similar increases were observed in rectal patients. Average 1-year costs per patient in 2009 were $106,461 and $102,680 for colon and rectal cancers, respectively, reflecting an increase of 32% and 20%, for patients who received antineoplastic agents. Median survival increased by about 6 and 10 months, respectively, for colon and rectal patients aged 65-74 who received antineoplastic agents, but an improvement of only 1 month of median survival was observed for patients 75+. CONCLUSIONS: Expensive multiple agent regimens are increasingly used in older mCRC patients. For patients aged 64-75 years, these treatments may be associated with several months of additional life, but patients aged 75+ may incur considerable expense without any survival benefit

Cancer · Colorectal cancer · Population · Colorectal Cancer Treatments and Studies · Economic and Financial Impacts of Cancer · Epidemiology · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Surgery

• Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients

  Kristin Linke, Gonzalo Tapia Rico et al.•Medical Care•2017

  Incluir item

• Use of High-cost Systemic Treatments in Elderly mCRC Patients

  Cathy J Bradley, K Robin Yabroff et al.•Medical Care•2017

  Incluir item

• Projections of the Cost of Cancer Care in the United States

  Angela B Mariotto, K Robin Yabroff et al.•CancerSpectrum Knowledge…•2011

  Incluir item

• Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients

  K Robin Yabroff, Joan L Warren et al.•Medical Care•2009

  Incluir item

• Utility of the Seer-Medicare Data to Identify Chemotherapy Use

  Joan L Warren, Linda C Harlan et al.•Medical Care•2002

  Incluir item

• Identifying Specific Chemotherapeutic Agents in Medicare Data

  Jennifer L Lund, Til Stürmer et al.•Medical Care•2013

  Incluir item